Clinical Trials
40 trialsTocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
Rifaximin in Patients With Monoclonal Gammopathy
Emory University
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
Stanford University
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
Centre Antoine Lacassagne
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Children's Oncology Group
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Northwestern University
Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins
National Institutes of Health Clinical Center (CC)
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias
National Institutes of Health Clinical Center (CC)
PAPE-MID
Inonu University
Identification of Nerves Using Fluorescein Sodium
Stanford University
REVEAL
Ono Pharmaceutical Co., Ltd.
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Dana-Farber Cancer Institute
RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study
Pfizer
BELINDA
Novartis
Pediatric Vaccinations
NYU Langone Health
Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment
University of Southern Denmark
An Endotracheal Tube Inserted to the Level of the Hypopharynx
American University of Beirut Medical Center
A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)
Dizal Pharmaceuticals
KEYNOTE145
Acerta Pharma BV
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
University of Washington
MK-1026-002
Merck Sharp & Dohme LLC
RITALLO
University Hospital, Bordeaux
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
Incyte Corporation
A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693
AstraZeneca
POLARIX
Hoffmann-La Roche
RISE Residents
McMaster University
SUper-Resolution Ultrasound Imaging of Erythrocytes (SURE) in Normal and Malignant Lymph Nodes
Rigshospitalet, Denmark
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
Feasibility Neurocognitive Outcome After Transplant
Stanford University
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
University of Michigan Rogel Cancer Center
SPiReL
Sunnybrook Health Sciences Centre
SevAsthma
Assistance Publique - Hôpitaux de Paris
SEIFEM
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
VR&depression
Sykehuset Innlandet HF
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Mayo Clinic
Physical Capacity in Hodgkin Lymphoma Survivors
University of Sao Paulo General Hospital